Data completeness
2/8 — Basic
Ruxolitinib (ruxolitinib) by Incyte is janus kinase inhibitors [moa].
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ruxolitinib is an oral small-molecule Janus Kinase (JAK) inhibitor developed by Incyte. It modulates immune signaling pathways by inhibiting JAK enzymes, which are central to inflammatory and hematologic disease mechanisms. The drug is currently in pre-launch phase, indicating active preparation for market entry.
Pre-Launch
Pre-launch status signals active team building across commercial, medical, and operations functions; significant career opportunity for professionals willing to invest in product launch execution.
Mechanism of Action
Janus Kinase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Started Aug 2026
324 enrolled
MyelofibrosisAnemia
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
Started Aug 2026
268 enrolled
MyelofibrosisMyelofibrosis (MF)
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
Started Jun 2026
24 enrolled
Sickle Cell DiseaseHematopoetic Stem Cell TransplantHaploidentical Hematopoietic Stem Cell Transplant+2 more
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Started Jun 2026
124 enrolled
LeukemiaMyelodysplasiaChronic Myelomonocytic Leukemia
Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)
Started Jun 2026
16 enrolled
Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
Worked on Ruxolitinib at Incyte? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.